Cited by 756Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Open access

Meyers, Paul A., Schwartz, Cindy L., Krailo, Mark D., Healey, John H., Bernstein, Mark L., Betcher, Donna, Ferguson, William S., Gebhardt, Mark C., Goorin, Allen M., Harris, Michael, Kleinerman, Eugenie, Link, Michael P., Nadel, Helen, Nieder, Michael, Siegal, Gene P., Weiner, Michael A., Wells, Robert J., Womer, Richard B., Grier, Holcombe E.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2008.14.0095

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 × 2 factorial design. The primary end points for analysis were EFS and overall survival. Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96). Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.14.0095

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,034
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citation
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
Souhami, R. L., Craft, A. W., van der Eijken, J. W., Nooij, M. A., Spooner, D. A., Bramwell, V. H. C., Wierzbicki, R. F., MALCOLM, A. J., Kirkpatrick, A., Uscinska, B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 381

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 201–300 of 756

Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 57
Progress and Opportunities for Immune Therapeutics in Osteosarcoma
Lettieri, C. K., Appel, N., Labban, N., Lussier, D. M., Blattman, J. N., & Hingorani, P. (2016) · Immunotherapy · doi:10.2217/imt-2016-0048 · Cited by 54
Identification of Potential Therapeutic Targets and Immune Cell Infiltration Characteristics in Osteosarcoma Using Bioinformatics Strategy
Niu, J., Yan, T., Guo, W., Wang, W. T., Zhao, Z., Ren, T., Huang, Y., Zhang, H., Yu, Y., & Liang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01628 · Cited by 54
Systemic Therapy for Osteosarcoma and Ewing Sarcoma
Meyers, P. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e644 · Cited by 49
Self-citation
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Bellera, C. A., Penel, N., Ouali, M., Bonvalot, S., Casali, P. G., Nielsen, O. S., Delannes, M., Litière, S., Bonnetain, F., Dabakuyo‐Yonli, T. S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu360 · Cited by 53
Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high‐grade, operable osteosarcomas of the extremities: A report from the Latin A merican Group of Osteosarcoma Treatment
Senerchia, A. A., Macedo, C. R. P. D., Ferman, S., Scopinaro, M. J., Cacciavillano, W., Boldrini, É., Moraes, V. L., Rey, G., de Oliveira, C. T., Castillo, L. A., et al. (2016) · Cancer · doi:10.1002/cncr.30411 · Cited by 54
Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
Evdokimova, V. E., Gassmann, H., Radvanyi, L. G., & Burdach, S. E. G. (2022) · Cancers · doi:10.3390/cancers15010272 · Cited by 58
Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells
Mu, X., Isaac, C. E., Schott, T., Huard, J., & Weiss, K. R. (2013) · Sarcoma · doi:10.1155/2013/480713 · Cited by 50
Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
Redondo, A., Bagué, S., Bernabéu, D., Ortiz-Cruz, E. J., Valverde, C. M., Alvarez, R. M., Martínez‐Trufero, J., Lopez-Martin, J. A., Correa, R., Cruz, J., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3436-0 · Cited by 52
Current questions in bone sarcomas
Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49
Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma
Withers, S. S., Skorupski, K. A., York, D. S., Choi, J. W., Woolard, K., Amorim, R. L., Sparger, E. E., Rodriguez, C. O., McSorley, S. J., Monjazeb, A. M., et al. (2018) · Veterinary and Comparative Oncology · doi:10.1111/vco.12444 · Cited by 52
Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy
Xu, C., Wang, M., Guo, W., Sun, W. Y., & Liu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672490 · Cited by 51
Natural killer cell therapy and aerosol interleukin‐2 for the treatment of osteosarcoma lung metastasis
Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., Hughes, D. P. M., Stewart, J., Wang, W., & Kleinerman, E. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24801 · Cited by 50
Self-citation
NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells
Foltz, J. A., Somanchi, S. S., Yang, Y., Aquino‐López, A., Bishop, E. E., & Lee, D. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00521 · Cited by 49
Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group
Isakoff, M. S., Barkauskas, D. A., Ebb, D. H., Morris, C. D., & Letson, D. G. (2012) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-012-2284-9 · Cited by 48
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
Sommer, B. C., Dhawan, D., Ratliff, T. L., & Knapp, D. W. (2018) · Bladder Cancer · doi:10.3233/blc-170145 · Cited by 50
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
Brard, C., Piperno-Neumann, S., Delaye, J., Brugières, L., Hampson, L. V., Teuff, G. L., Deley, M. L., & Gaspar, N. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025877 · Cited by 48
Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology Group
Hingorani, P., Seidel, K. D., Krailo, M., Mascarenhas, L., Meyers, P. A., Marina, N. M., Conrad, E. U., & Hawkins, D. S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23129 · Cited by 48
Self-citation
Biomarkers in osteosarcoma
Kong, C., & Hansen, M. F. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050802608496 · Cited by 47
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2
Meazza, C., Cefalo, G., Massimino, M., Daolio, P. A., Pastorino, U., Scanagatta, P., Morosi, C., Podda, M. G., Ferrari, A., Terenziani, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1052-9 · Cited by 47
Strategies and developments of immunotherapies in osteosarcoma
WAN, J., Zhang, X., Liu, T., & Zhang, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3962 · Cited by 46
Molecular pathogenesis and therapeutic strategies of human osteosarcoma
Denduluri, S. K., Wang, Z., Yan, Z., Wang, J., Wei, Q., Mohammed, M. K., Haydon, R. C., Luu, H. H., & He, T. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150075 · Cited by 45
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial
WICKI, A. N., Ritschard, R., Loesch, U., Deuster, S., Rochlitz, C. F., & Mamot, C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.034 · Cited by 46
NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases
Pashenkov, M. V., Dagil, Y. A., & Pinegin, B. V. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.036 · Cited by 48
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
Rettew, A. N., Young, E. D., Lev, D. C., Kleinerman, E. S., Abdul‐Karim, F. W., Getty, P. J., & Greenfield, E. M. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.34 · Cited by 43
Self-citation
Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy
Ballatori, S. E., & Hinds, P. W. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.1 · Cited by 45
PERK-mediated Autophagy in Osteosarcoma Cells Resists ER Stress-induced Cell Apoptosis
Ji, G., Yu, N., Xue, X., & Li, Z.-G. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11100 · Cited by 44
Segmentation of osteosarcoma in MRI images by K‐means clustering, Chan‐Vese segmentation, and iterative Gaussian filtering
Nasor, M., & Obaid, W. (2020) · IET Image Processing · doi:10.1049/ipr2.12106 · Cited by 43
Treatment of Bone Tumors
Rajani, R., & Gibbs, C. P. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2011.07.015 · Cited by 42
Repurposing Infectious Diseases Vaccines Against Cancer
Vandeborne, L., Pantziarka, P., Nuffel, A. M. T. V., & Bouche, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688755 · Cited by 42
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 42
BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation
Lewis, V. O., Devarajan, E., Cardó‐Vila, M., Thomas, D. G., Kleinerman, E. S., Marchiò, S., Sidman, R. L., Pasqualini, R., & Arap, W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704173114 · Cited by 41
Self-citation
Management of Bone Tumours in Paediatric Oncology
Bölling, T., Hardes, J., & Dirksen, U. (2012) · Clinical Oncology · doi:10.1016/j.clon.2012.07.010 · Cited by 41
Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis
Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., & Kleinerman, E. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25019 · Cited by 40
Self-citation
Translation of peptidoglycan metabolites into immunotherapeutics
Griffin, M. E., Hespen, C. W., Wang, Y., & Hang, H. C. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1095 · Cited by 41
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 45
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review
Jimmy, R., Stern, C., Lisy, K., & White, S. (2017) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003105 · Cited by 39
Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution
Wang, W., Yang, J., Wang, Y., Wang, D., Han, G., Jia, J., Xu, M., & Bi, W. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.11.009 · Cited by 39
Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation
Kany, S., Woschek, M., Kneip, N., Sturm, R., Kalbitz, M., Hanschen, M., & Relja, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4288 · Cited by 39
Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy
Rivera-Valentin, R. K., Zhu, L., & Hughes, D. P. M. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0134-4 · Cited by 40
Data-Driven Mathematical Model of Osteosarcoma
Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single‐center experience of 237 patients
Nataraj, V., Batra, A., Rastogi, S., Khan, S. A., Sharma, M. C., Vishnubhatla, S., & Bakhshi, S. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24045 · Cited by 38
Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma
Tsuda, Y., Tsoi, K. M., Parry, M., Stevenson, J. D., Fujiwara, T., Sumathi, V. P., & Jeys, L. M. (2020) · The Bone & Joint Journal · doi:10.1302/0301-620x.102b6.bjj-2019-1307.r1 · Cited by 38
Immunotherapy for osteosarcoma
Yahiro, K., & Matsumoto, Y. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1824499 · Cited by 38
Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
Lavaud, M., Mullard, M., Tesfaye, R. A., Amiaud, J., Legrand, M., Danieau, G., Brion, R., Morice, S., Regnier, L., Dupuy, M., et al. (2021) · Cells · doi:10.3390/cells10092268 · Cited by 38
Immune-Based Therapies for Sarcoma
Pollack, S. M., Loggers, E. T., Rodler, E. T., Yee, C., & Jones, R. L. (2011) · Sarcoma · doi:10.1155/2011/438940 · Cited by 37
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
Goldberg, J. L., & Sondel, P. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.012 · Cited by 36
MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion
Liu, Y.-J., Li, W., Feng, C., Liu, J.-N., Lin, J., & Chen, D. (2017) · Oncology Reports · doi:10.3892/or.2017.6142 · Cited by 37
Retracted
Using the Spleen as anIn VivoSystemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy withα-PD-L1
Markel, J., Noore, J., Emery, E. J., Bobnar, H. J., Kleinerman, E. S., & Lindsey, B. A. (2018) · Sarcoma · doi:10.1155/2018/8694397 · Cited by 38
Self-citation
Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group
Tanaka, K., & Ozaki, T. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa231 · Cited by 37
Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults
Eleutério, S. J. P., Senerchia, A. A., Almeida, M. T., da Costa, C. M. L., Lustosa, D., Calheiros, L. M., Barreto, J. H., Brunetto, A. L., Macedo, C. R. P. D., & Petrilli, A. S. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25459 · Cited by 36
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases
Mori, K., Ando, K., & Heymann, D. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.151 · Cited by 37
Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy
Meadors, J. L., Cui, Y., Chen, Q., Song, Y., Khan, J. I., Merlino, G. T., Tsokos, M., Orentas, R. J., & Mackall, C. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23048 · Cited by 37
Modeling human osteosarcoma in the mouse: From bedside to bench
Janeway, K. A., & Walkley, C. R. (2010) · Bone · doi:10.1016/j.bone.2010.07.028 · Cited by 36
Malignant Osseous Tumors of the Pediatric Spine
Kim, H. J., McLawhorn, A. S., Goldstein, M. J., & Boland, P. J. (2012) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201210000-00004 · Cited by 36
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.
Biteau, K., Guiho, R., Chatelais, M., Taurelle, J., Chesneau, J., Corradini, N., Heymann, D., & Rédiní, F. (2016) · PubMed Central · Cited by 36
Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2)
Palmerini, E., Meazza, C., Tamburini, A., Bisogno, G., Ferraresi, V., Asaftei, S. D., Milano, G. M., Coccoli, L., Manzitti, C., Luksch, R., et al. (2022) · Cancer · doi:10.1002/cncr.34131 · Cited by 35
The diagnosis and treatment of osteosarcoma and Ewing’s sarcoma in children and adolescents
Zarghooni, K., Bratke, G., Landgraf, P., Simon, T., Maintz, D. C., & Eysel, P. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0079 · Cited by 40
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment
Venkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12260 · Cited by 35
A 20-year retrospective analysis of CT-based pre-operative identification of pulmonary metastases in patients with osteosarcoma: A single-center review
Heaton, T. E., Hammond, W. J., Farber, B. A., Pallos, V., Meyers, P. A., Chou, A. J., Price, A. P., & LaQuaglia, M. P. (2016) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2016.10.034 · Cited by 35
Self-citation
Polysaccharides from Dendrobium officinale inhibit proliferation of osteosarcoma cells and enhance cisplatin-induced apoptosis
Zhang, X., Duan, S., Tao, S., Huang, J., Liu, C., Xing, S., Ren, Z., Lei, Z., Li, Y., & Wei, G. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104143 · Cited by 35
Immune classification of osteosarcoma
Le, T., Department of Mathematics and Statistics, U. O. M. A., Su, S., & Shahriyari, L. (2021) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2021098 · Cited by 35
Immunotherapy for sarcomas
Nakata, E., Fujiwara, T., Kunisada, T., Ito, T., Takihira, S., & Ozaki, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab005 · Cited by 36
Serum tumor markers in pediatric osteosarcoma: a summary review
Savitskaya, Y., Rico-Martínez, G., Linares-González, L. M., Delgado-Cedillo, E. A., Tellez-Gastelum, R. M., Alfaro-Rodríguez, A., Redón-Tavera, A., & de León, J. C. I.-P. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-9 · Cited by 35
Maximum benefit of chemotherapy for osteosarcoma achieved—what are the next steps?
Kleinerman, E. S. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30270-4 · Cited by 34
Self-citation
Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics
Li, Y., Liu, Q. H., Tian, J., He, H., & Luo, W. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.12.004 · Cited by 36
Safety and efficacy of high‐dose methotrexate for osteosarcoma in adolescents compared with young adults
Wippel, B., Gundle, K. R., Dang, T., Paxton, J., Bubalo, J. S., Stork, L. C., Fu, R. F., Ryan, C. W., & Davis, L. E. (2018) · Cancer Medicine · doi:10.1002/cam4.1898 · Cited by 34
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival
Hung, G., Yen, H., Yen, C., Chen, W., Chen, P. C.-H., Wu, H.-T. H., Chiou, H., Chang, W., & Hsu, H.-E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4154-z · Cited by 34
Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)
Ferrari, S., Meazza, C., Palmerini, E., Tamburini, A., Fagioli, F., Cozza, R., Ferraresi, V., Bisogno, G., Mascarin, M., Cefalo, G., et al. (2014) · Tumori Journal · doi:10.1177/1778.19262 · Cited by 34
Big peptide drugs in a small molecule world
Otvos, L. J., & Wade, J. D. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1302169 · Cited by 33
miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity
Zou, Y., Huang, Y., Yang, J., Wu, J., & Luo, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6187 · Cited by 33
Retracted
The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
van Hoogevest, P., Tiemessen, H. L. G. M., Metselaar, J. M., Drescher, S., & Fahr, A. (2021) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.202000297 · Cited by 33
SELNET clinical practice guidelines for bone sarcoma
Blay, J., Palmerini, E., Bollard, J., Aguiar, S., Angel, M. O., Araya, B. B., Badilla, R., Bernabéu, D., Campos, F. A. B., Caro-Sánchez, C. H. S., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103685 · Cited by 34
Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery
Simpson, S., Rizvanov, A. A., Jeyapalan, J. N., de Brot, S., & Rutland, C. S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.965391 · Cited by 38
Malignant and Metastatic Tumors of the Hand
Puhaindran, M. E., & Athanasian, E. A. (2010) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2010.08.014 · Cited by 32
Knockdown of Long Noncoding RNA TUG1 Inhibits the Proliferation and Cellular Invasion of Osteosarcoma Cells by Sponging miR-153
Wang, H., Yu, Y., Fan, S., & Luo, L. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14908298412505 · Cited by 32
Retracted
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
Penel-Page, M., Ray-Coquard, I., Larcade, J., Girodet, M., Bouclier, L., Rogasik, M., Corradini, N., Entz-Werle, N., Brugieres, L., Domont, J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1894-5 · Cited by 32
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
Fan, X.-L., Cai, G.-P., Zhu, L.-L., & Ding, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s91217 · Cited by 32
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31
Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray
Jentzsch, T., Robl, B., Husmann, M., Bode‐Lesniewska, B., & Fuchs, B. (2014) · PubMed · doi:10.5167/uzh-98588 · Cited by 32
Circular RNA circ_0081001 knockdown enhances methotrexate sensitivity in osteosarcoma cells by regulating miR-494-3p/TGM2 axis
Wei, W., Ji, L., Duan, W., & Zhu, J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-02169-5 · Cited by 32
State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma
Meazza, C., & Asaftei, S. D. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1936499 · Cited by 29
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, A. R., Chen, Y., Scharschmidt, T. J., Xue, W., Gao, Z., Black, J. O., Choy, E., Davis, J. L., Fanburg–Smith, J. C., Kao, S. C.-S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00045 · Cited by 31
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
Venkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12261 · Cited by 31
A Randomized Study on Postrelapse Disease‐Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients
Longhi, A., Reif, M., Mariani, E., & Ferrari, S. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/210198 · Cited by 30
Intensive Induction Chemotherapy without Methotrexate in Adult Patients with Localized Osteosarcoma: Results of the Institut Gustave-Roussy Phase II Trial
Assi, H. I., Missenard, G., Terrier, P., Pechoux, C. L., Bonvalot, S., Vanel, D., Méric, J., Tursz, T., & Cesne, A. L. (2010) · Current Oncology · doi:10.3747/co.v17i6.578 · Cited by 30
Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?
Gomez‐Brouchet, A., Gilhodes, J., Acker, N. V., Brion, R., Bouvier, C., Assémat, P., Gaspar, N., Aubert, S., Guinebretière, J., Marie, B., et al. (2021) · Cancers · doi:10.3390/cancers13030423 · Cited by 30
Advances in the Treatment of Pediatric Bone Sarcomas
Grohar, P. J., Janeway, K. A., Maese, L. D., & Schiffman, J. D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175378 · Cited by 30
Endothelin-1 Promotes Osteosarcoma Cell Invasion and Survival against Cisplatin-induced Apoptosis
Zhao, Y.-T., Liao, Q., Zhu, Y., & Long, H. (2011) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-011-1939-2 · Cited by 30
Complexities in Interpretation of Osteosarcoma Clinical Trial Results
Hunsberger, S., Freidlin, B., & Smith, M. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3484 · Cited by 30
European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma
van Ewijk, R., Herold, N., Baecklund, F., Baumhoer, D., Boye, K., Gaspar, N., Harrabi, S., Haveman, L., Hecker‐Nolting, S., Hiemcke‐Jiwa, L. S., et al. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100029 · Cited by 33
Advances in Therapy for Pediatric Sarcomas
Weiss, A. R., Gill, J. B., Goldberg, J., Lagmay, J., Spraker‐Perlman, H. L., Venkatramani, R., & Reed, D. R. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0395-z · Cited by 28
AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway
Liu, Y., Leng, A., Li, L., Yang, B. H., Shen, S., Chen, H., Zhu, E., Xu, Q., Ma, X., Shi, P., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04744-6 · Cited by 29
Immunotherapy for Bone and Soft Tissue Sarcomas
Uehara, T., Fujiwara, T., Takeda, K., Kunisada, T., Ozaki, T., & Udono, H. (2015) · BioMed Research International · doi:10.1155/2015/820813 · Cited by 30
High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy
Yang, C., Gao, R., Wang, J., Yuan, W., Wang, C., & Zhou, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-1833-0 · Cited by 29
The future of immunotherapy for sarcoma
Tsukahara, T., Emori, M., Murata, K., Mizushima, E., Shibayama, Y., Kubo, T., Kanaseki, T., Hirohashi, Y., Yamashita, T., Sato, N., et al. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1188075 · Cited by 31
Management of Bone Sarcoma
Gutowski, C. J., Basu-Mallick, A., & Abraham, J. A. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.06.002 · Cited by 29
Novel targets with potential therapeutic applications in osteosarcoma
Khanna, C. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0054-3 · Cited by 29
Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
Withers, S. S., York, D. S., Choi, J. W., Woolard, K., Amorim, R. L., Sparger, E. E., Burton, J. H., McSorley, S. J., Monjazeb, A. M., Murphy, W. J., et al. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12459 · Cited by 29
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza, C., Bastoni, S., & Scanagatta, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760848 · Cited by 28

Authors: Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., Kleinerman, E., Link, M. P., Nadel, H., Nieder, M., Siegal, G. P., Weiner, M. A., Wells, R. J., Womer, R. B., & Grier, H. E.
Affiliations: Children's Oncology Group (US)
ORCID: Meyers, Paul A.
Schwartz, Cindy L.
Krailo, Mark D.
Healey, John H.
Bernstein, Mark L.
Ferguson, William S.
Kleinerman, Eugenie
Nadel, Helen
Siegal, Gene P.
Womer, Richard B.
Grier, Holcombe E.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-02-01
Volume: 26
Issue: 4
Pages: 633-638
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.14.0095
OpenAlex: W2103405666
Cited by: 752
References: 20
Citations by year: 2026: 21 · 2025: 30 · 2024: 30 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 70 · 2019: 39 · 2018: 38 · 2017: 55 · 2016: 49 · 2015: 50 · 2014: 57 · 2013: 46 · 2012: 36
FWCI: 33.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Children’s Oncology Group
National Institutes of Health (CA98543)
National Cancer Institute (U10CA098543, CA-98543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: osteosarcoma, muramyl tripeptide, ifosfamide, cisplatin, doxorubicin, methotrexate, event-free survival, overall survival, pediatric cancer chemotherapy, immunomodulatory therapy, surgical resection
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Doxorubicin, Female, Humans, Ifosfamide, Infant, Lung Neoplasms, Male, Methotrexate, Neoplasm Recurrence, Local, Osteosarcoma, Survival Rate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks